Medical disclaimer

trulicity.us.com publishes educational health information for general awareness only. Nothing on this website is, or is intended to be, a substitute for professional medical advice, diagnosis, or treatment. You should always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or a medication.

Never disregard professional medical advice or delay seeking it because of something you have read on this website. Never start, stop, or change the dose of any medication — including Trulicity (dulaglutide) — without consulting a licensed clinician who knows your medical history. If you think you may be experiencing a medical emergency, call your local emergency number or visit the nearest emergency department immediately.

Uncontrolled type 2 diabetes is a serious medical condition with significant short- and long-term risks, including diabetic ketoacidosis, kidney damage, vision loss, nerve damage, cardiovascular events, and death. Patients currently prescribed Trulicity should not discontinue or reduce the dose without medical supervision.

Affiliate disclosure

This website contains affiliate links to third-party telehealth providers. "Affiliate links" mean that when a visitor clicks through one of our links and completes a qualifying action (such as starting an eligible online consultation), we may receive a commission from the third-party provider at no additional cost to the visitor.

We mark all paid commercial links with the rel="sponsored nofollow noopener" attribute, which is Google's and Bing's documented way of indicating a paid or commercial relationship and preventing the transfer of search ranking equity. This website does not use URL cloaking, bot detection, or any other technique intended to hide the commercial nature of its links from search engines or from visitors.

Affiliate relationships do not influence our editorial content. Drug comparisons, dosing discussions, side-effect descriptions, and clinical trial summaries are based on publicly available sources (FDA labels, peer-reviewed publications, manufacturer pricing disclosures) and are not edited to favor any product or provider.

Drug information and trademarks

Trulicity® is a registered trademark of Eli Lilly and Company. Trulicity (dulaglutide) is FDA-approved for the treatment of type 2 diabetes mellitus in adults and in pediatric patients 10 years of age and older, and for the reduction of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. Trulicity is not FDA-approved for chronic weight management. Off-label use of Trulicity for weight loss is not endorsed or recommended by this website.

Ozempic®, Rybelsus®, Wegovy®, Victoza®, and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Byetta® and Bydureon® are registered trademarks of AstraZeneca.

Use of these trademarks on this website is for identification and editorial reference only and does not indicate any affiliation with, endorsement by, or sponsorship from any of these companies. trulicity.us.com is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.

Weight-loss disclaimer

Weight change on Trulicity is a secondary effect of treatment, not the medication's FDA-approved indication. In published phase-3 clinical trials (AWARD program), mean weight loss on Trulicity ranged from approximately 1–5 kilograms depending on dose and study duration, corresponding to roughly 2–5% of starting body weight. Individual results vary; some patients lose more, some lose less, and some gain weight.

FDA-approved chronic weight management medications — including Wegovy® (semaglutide 2.4 mg) and Zepbound® (tirzepatide) — have been studied at different doses and in different patient populations than Trulicity and may produce different results. No weight loss medication is a substitute for a sustainable pattern of healthy eating, physical activity, and clinician follow-up. No weight loss medication is guaranteed to produce any specific weight loss outcome.

Switching disclaimer

Any switch between diabetes medications or between GLP-1 drug classes must be performed under the supervision of a licensed healthcare provider. Dose-conversion information on this website is provided for educational purposes to help patients have informed conversations with their clinician — it is not a self-administration guide. Do not self-adjust, stop, or replace any prescribed medication on the basis of information on this or any other website.

Legal and lawsuit information

Summaries of GLP-1 litigation on this website are informational only and do not constitute legal advice or a recommendation to pursue or refrain from pursuing a legal claim. If you believe you have been harmed by any medication, consult a licensed attorney in your jurisdiction.

External links

This website links to external resources (regulatory agency pages, clinical trial publications, and affiliate partners). We are not responsible for the content, accuracy, or privacy practices of external websites.

Contact

Corrections and editorial comments: send an email to [contact email to be added]. We aim to review factual corrections within a reasonable timeframe.